Loxo Oncology Company Profile (NASDAQ:LOXO)

About Loxo Oncology

Loxo Oncology logoLoxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LOXO
  • CUSIP:
Key Metrics:
  • Previous Close: $27.78
  • 50 Day Moving Average: $25.89
  • 200 Day Moving Average: $24.17
  • 52-Week Range: $16.21 - $35.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.17
  • P/E Growth: 0.00
  • Market Cap: $601.83M
  • Outstanding Shares: 21,664,000
  • Beta: 2.47
Additional Links:
Companies Related to Loxo Oncology:

Analyst Ratings

Consensus Ratings for Loxo Oncology (NASDAQ:LOXO) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.00 (7.99% upside)

Analysts' Ratings History for Loxo Oncology (NASDAQ:LOXO)
DateFirmActionRatingPrice TargetDetails
7/13/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/19/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$30.00View Rating Details
4/18/2016Stifel NicolausReiterated RatingBuy$36.00View Rating Details
3/16/2016Citigroup Inc.Boost Price TargetBuy$24.00 -> $25.00View Rating Details
11/11/2015JMP SecuritiesBoost Price Target$26.00 -> $29.00View Rating Details
9/2/2014Leerink SwannInitiated CoverageOutperform$20.00View Rating Details
(Data available from 8/31/2014 forward)


Earnings History for Loxo Oncology (NASDAQ:LOXO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q2($0.63)($0.77)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014($12.27)($14.46)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Loxo Oncology (NASDAQ:LOXO)
Current Year EPS Consensus Estimate: $-2.83 EPS
Next Year EPS Consensus Estimate: $-3.40 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.77)($0.49)($0.63)
Q2 20161($0.61)($0.61)($0.61)
Q3 20161($0.63)($0.63)($0.63)
Q4 20161($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)


Dividend History for Loxo Oncology (NASDAQ:LOXO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Loxo Oncology (NASDAQ:LOXO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.00View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Loxo Oncology (NASDAQ:LOXO)
News IconLoxo Oncology Inc. (LOXO): OrbiMed Advisors Reports Percentage of Ownership Change (NASDAQ:LOXO)
feedproxy.google.com - August 8 at 9:24 AM
biz.yahoo.com logoArray Biopharma Inc Earnings Call (Q4 2016) (NASDAQ:LOXO)
biz.yahoo.com - August 4 at 9:03 AM
twst.com logoLoxo Oncology Inc.: Loxo Oncology Announces Second Quarter 2016 Financial Results (NASDAQ:LOXO)
www.twst.com - August 4 at 9:03 AM
streetinsider.com logoForm 8-K Loxo Oncology, Inc. For: Aug 03 (NASDAQ:LOXO)
www.streetinsider.com - August 4 at 9:03 AM
sg.finance.yahoo.com logoLoxo reports 2Q loss (NASDAQ:LOXO)
sg.finance.yahoo.com - August 3 at 9:18 AM
publicnow.com logoLoxo Oncology to Announce Second Quarter 2016 Financial Results (NASDAQ:LOXO)
www.publicnow.com - July 27 at 7:08 AM
finance.yahoo.com logoLoxo Oncology (LOXO) Looks Good: Stock Adds 6% in Session (NASDAQ:LOXO)
finance.yahoo.com - July 14 at 8:00 AM
finance.yahoo.com logoLoxo Oncology Gets Breakthrough Therapy Status From FDA For LOXO-101 (NASDAQ:LOXO)
finance.yahoo.com - July 13 at 10:45 AM
publicnow.com logoLoxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 (NASDAQ:LOXO)
www.publicnow.com - July 13 at 9:28 AM
zacks.com logoNew Strong Buy Stocks for July 13th (NASDAQ:LOXO)
www.zacks.com - July 13 at 8:56 AM
publicnow.com logoLoxo Oncology Accepts Invitation to Present LOXO-101 to the FDA’s Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (NASDAQ:LOXO)
www.publicnow.com - June 15 at 9:09 AM
publicnow.com logoLoxo Oncology to Present at the JMP Securities Life Sciences Conference (NASDAQ:LOXO)
www.publicnow.com - June 14 at 6:59 AM
4-traders.com logoLOXO ONCOLOGY, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K) (NASDAQ:LOXO)
www.4-traders.com - June 13 at 5:38 PM
biz.yahoo.com logoLOXO ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of (NASDAQ:LOXO)
biz.yahoo.com - June 13 at 4:32 PM
News IconPharma lobby 'fighting back' on drug prices (NASDAQ:LOXO)
www.journalgazette.net - June 12 at 5:53 PM
News IconPharma group punches back on drug prices as pressure rises (NASDAQ:LOXO)
www.chicagotribune.com - June 10 at 6:11 PM
capitalcube.com logoLoxo Oncology, Inc. :LOXO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 (NASDAQ:LOXO)
www.capitalcube.com - June 2 at 12:57 PM
News IconBrokerage Analyst Buys: Solar Capital Ltd. (NYSE:SLRA), TESARO, Inc. (NASDAQ:TSRO), Alcobra Ltd. (NASDAQ ... - RiversideGazette.com (NASDAQ:LOXO)
www.riversidegazette.com - February 26 at 1:42 PM
News IconLoxo Oncology Incorporated (NASDAQ:LOXO) Shorted Shares Increased 9.68% After Market Selling - Stock Caller (NASDAQ:LOXO)
www.stockcaller.com - February 26 at 1:42 PM
News IconLoxo Oncology, Inc: Aisling Capital Iii Lp increased Its Holding - fdanewsalert.com (NASDAQ:LOXO)
www.fdanewsalert.com - February 7 at 2:33 PM
News IconCompany Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) Rally 3.51% - Bull Report (NASDAQ:LOXO)
www.bullreport.news - January 31 at 1:35 PM
investornewswire.com logoLoxo Oncology, Inc. (NASDAQ:LOXO) - Stock Sentiment And ABR Update - Investor Newswire (NASDAQ:LOXO)
www.investornewswire.com - January 25 at 1:38 PM
noodls.com logoLoxo Oncology Announces EMA Orphan Drug Designation Granted to LOXO-101 for Treatment of Soft Tissue Sarcoma (NASDAQ:LOXO)
www.noodls.com - January 15 at 7:12 AM
finance.yahoo.com logoCoverage initiated on Loxo Oncology by Citigroup (NASDAQ:LOXO)
finance.yahoo.com - January 15 at 7:09 AM
finance.yahoo.com logo6:45 am Loxo Oncology: The European Medicines Agency has granted the co orphan drug designation for LOXO-101 for treatment of patients with soft tissue sarcoma (NASDAQ:LOXO)
finance.yahoo.com - January 15 at 6:45 AM
biz.yahoo.com logoLOXO ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:LOXO)
biz.yahoo.com - January 7 at 4:02 PM
noodls.com logoLoxo Oncology Announces First Patient Enrolled in Phase 1 Trial of LOXO-101 in Pediatric Cancer Patients (NASDAQ:LOXO)
www.noodls.com - December 22 at 7:20 AM
finance.yahoo.com logoLOXO ONCOLOGY, INC. Financials (NASDAQ:LOXO)
finance.yahoo.com - December 8 at 1:17 PM
noodls.com logoLoxo Oncology Announces the Closing of Its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares (NASDAQ:LOXO)
www.noodls.com - November 17 at 4:59 PM
biz.yahoo.com logoLOXO ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement (NASDAQ:LOXO)
biz.yahoo.com - November 12 at 4:06 PM
noodls.com logoLoxo Oncology Prices Follow-On Offering of Common Stock (NASDAQ:LOXO)
www.noodls.com - November 11 at 7:16 PM
noodls.com logoLoxo Oncology Announces Proposed Public Offering of Common Stock (NASDAQ:LOXO)
www.noodls.com - November 10 at 4:26 PM
noodls.com logoLoxo Oncology to Present at Upcoming Investor Conferences (NASDAQ:LOXO)
www.noodls.com - November 10 at 7:16 AM
noodls.com logoLoxo Oncology Announces Third Quarter 2015 Financial Results and Provides Program Updates (NASDAQ:LOXO)
www.noodls.com - November 10 at 7:16 AM


Loxo Oncology (NASDAQ:LOXO) Chart for Wednesday, August, 31, 2016

Last Updated on 8/31/2016 by MarketBeat.com Staff